Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 4/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610368 | 1.00 | CYP2D6 (0.36) | CYP2D6RENAKT1AKT2AKT3 | |
| SCHEMBL4790175 | 1.00 | CYP2D6 (0.36) | CYP2D6RENAKT1AKT2AKT3 | |
| SCHEMBL2027347 | 0.96 | CYP2D6 (0.33) | CYP2D6REN | |
| SCHEMBL4071173 | 0.96 | CYP2D6 (0.33) | CYP2D6REN | |
| SCHEMBL3604264 | 0.87 | CNR2 (0.32) | CYP2D6 | |
| SCHEMBL1866433 | 0.83 | CYP2D6 (0.46) | CYP2D6RENAKT1AKT2AKT3 | |
| SCHEMBL1862530 | 0.83 | CYP2D6 (0.46) | CYP2D6RENAKT1AKT2AKT3 | |
| SCHEMBL3615804 | 0.82 | CNR2 (0.32) | REN | |
| SCHEMBL4975133 | 0.82 | CNR2 (0.32) | REN | |
| SCHEMBL2996749 | 0.82 | CNR2 (0.32) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | CYP2D6 1294/4885REN 2/4885AKT1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.